Tema Oncology ETF (CANC)

Assets	$70.08M
Expense Ratio	0.75%
PE Ratio	20.39
Shares Out	2.63M
Dividend (ttm)	$0.73
Dividend Yield	2.73%
Ex-Dividend Date	Dec 11, 2024
Payout Frequency	Annual
Payout Ratio	55.73%

Volume	10,643
Open	26.80
Previous Close	26.71
Day's Range	26.53 - 26.80
52-Week Low	20.10
52-Week High	30.11
Beta	1.00
Holdings	52
Inception Date	Aug 15, 2023

About CANC

Fund Home Page

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.

• Asset Class: Equity
• Category: Health
• Stock Exchange: NASDAQ
• Ticker Symbol: CANC
• ETF Provider: Tema

Top 10 Holdings

43.79% of assets

Name	Symbol	Weight
BridgeBio Pharma, Inc.	BBIO	5.56%
Revolution Medicines, Inc.	RVMD	5.52%
Roche Holding AG	RHHBY	4.93%
Novartis AG	NOVN	4.58%
Merus N.V.	MRUS	4.39%
AstraZeneca PLC	AZN	4.36%
Genmab A/S	GMAB	4.24%
Eli Lilly and Company	LLY	4.00%
Nuvalent, Inc.	NUVL	3.13%
Arcellx, Inc.	ACLX	3.08%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 11, 2024	$0.72827	Dec 12, 2024
Dec 13, 2023	$0.14911	Dec 15, 2023

Performance

CANC had a total return of -7.82% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.72%.